We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
How does West respond to increased demand to produce supplies needed for use with treatments to combat the coronavirus? The answer is – with years of experience, careful planning, and a robust manufacturing program. We are committed to doing our part to speed the successful development and large-scale manufacture of high-quality components required to serve customer needs for the delivery of a safe, effective COVID-19 vaccine, which includes expanding labor and equipment resources.
West has been working to support the changing demands of our customers for more than 97 years. We are a leading provider of packaging components and delivery systems for injectable drugs and healthcare products. Our extensive global network of 25 manufacturing sites across the globe is supporting customers with the production of elastomer stoppers, plungers and aluminum seals. Overall, West produces about 40 billion components and devices a year.
Our products continue to create value for our customers. The choice of which high-quality components (vials, stoppers, seals, etc.) are used with injectable medicines, including vaccines, is a complex one driven by years of science which West has pioneered. We are working with customers in the selection, testing and verification of compatible components with a specific drug, formal stability testing, and scenario planning for potential scale-up should the drug be successful in its clinical trials.
We are proud of the foundation we have built to offer solutions in response to the increased demands of our customers during this time. And we are proud of the important contribution we make as our products are used daily by millions of patients across the globe.
When choosing a resource for laboratory testing, pharmaceutical manufacturers face a difficult decision. Which is the better option – an independent facility or a supplier-affiliated laboratory?
<p>West is proud to announce our inaugural Corporate Responsibility (CR) Report that is now live on the West website. We strive to uphold and surpass industry standards for CR around the globe, and this report gives us the opportunity to outline how West’s initiatives have shaped our culture and are vital to the success of our business. </p><p>West’s 2016 Corporate Responsibility Report highlights five key areas that we believe are most important to our business and stakeholders:</p><ul><li>Compliance and Ethics</li><li>Philanthropy</li><li>Diversity</li><li>Health and Safety</li><li>Environmental Sustainability</li></ul><p>Below is Part One of a blog series, highlighting our commitment to Compliance and Ethics.</p>
The impact of a cancer diagnosis can be stressful. Questions such as “how will I tell my family?”, “how will I afford to pay my bills?”, “will I ever work again?” and even “will I survive?” <span>are at the forefront of the patient’s mind as they process their diagnosis and begin treatment</span>. So, how can the patient experience with treatment be supported? By offering the best quality of care.
The coring and fragmentation of elastomer components used in containment of parenteral drug products continues to be a challenge. Many factors influence these phenomena, so it is critical that a pharmaceutical manufacturer understands how a vial system will be used, for example: what is the recommended needle gauge, is it single- or multi-dose, could spikes, vial adapters or closed system transfer devices be used. Cores and fragments can be generated by needle penetration of the elastomer components. Cores are formed by the needle cannula cutting the elastomer – ordinarily they are cylindrical. Fragments are formed via an abrasion phenomenon of the needle penetration – shapes are irregular. <br />
<p><em>Component manufacturing process designed with Quality by Design principles meets the high-quality needs of pharmaceutical manufacturers and patients </em></p><p>West has introduced a new line of high-quality components under its NovaPure brand at the PDA Annual Meeting. Through a product development process that incorporates Quality by Design principles, NovaPure components, including serum and lyophilization stoppers and syringe plungers, will help to ensure the safety, efficacy and purity of injectable drug products.</p>
English
Chinese
